Redeye upgrades Remedy’s 2020-21 earnings estimates substantially following the full-year 2019 report, our key take away from which was the company’s positive outlook statement. Indeed, we expect Control (which we believe has had a head start to the year) to drive higher revenues and earnings in 2020, one of several catalysts with potential to take the stock higher still.